|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNST |
Gene summary for CNST |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNST | Gene ID | 163882 |
| Gene name | consortin, connexin sorting protein | |
| Gene Alias | C1orf71 | |
| Cytomap | 1q44 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6PJW8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 163882 | CNST | LZE2T | Human | Esophagus | ESCC | 2.45e-04 | 4.56e-01 | 0.082 |
| 163882 | CNST | LZE4T | Human | Esophagus | ESCC | 4.03e-15 | 5.11e-01 | 0.0811 |
| 163882 | CNST | LZE7T | Human | Esophagus | ESCC | 4.42e-07 | 4.33e-01 | 0.0667 |
| 163882 | CNST | LZE8T | Human | Esophagus | ESCC | 9.71e-04 | 2.28e-01 | 0.067 |
| 163882 | CNST | LZE20T | Human | Esophagus | ESCC | 6.83e-07 | 1.39e-01 | 0.0662 |
| 163882 | CNST | LZE24T | Human | Esophagus | ESCC | 9.33e-27 | 8.39e-01 | 0.0596 |
| 163882 | CNST | LZE21T | Human | Esophagus | ESCC | 1.53e-03 | 3.07e-01 | 0.0655 |
| 163882 | CNST | P1T-E | Human | Esophagus | ESCC | 2.06e-03 | 4.36e-01 | 0.0875 |
| 163882 | CNST | P2T-E | Human | Esophagus | ESCC | 5.45e-23 | 3.10e-01 | 0.1177 |
| 163882 | CNST | P4T-E | Human | Esophagus | ESCC | 5.91e-09 | 2.63e-01 | 0.1323 |
| 163882 | CNST | P5T-E | Human | Esophagus | ESCC | 8.80e-18 | 4.49e-01 | 0.1327 |
| 163882 | CNST | P8T-E | Human | Esophagus | ESCC | 1.95e-25 | 4.55e-01 | 0.0889 |
| 163882 | CNST | P9T-E | Human | Esophagus | ESCC | 3.99e-15 | 4.10e-01 | 0.1131 |
| 163882 | CNST | P10T-E | Human | Esophagus | ESCC | 3.43e-13 | 2.79e-01 | 0.116 |
| 163882 | CNST | P11T-E | Human | Esophagus | ESCC | 1.98e-13 | 6.26e-01 | 0.1426 |
| 163882 | CNST | P12T-E | Human | Esophagus | ESCC | 6.71e-32 | 6.70e-01 | 0.1122 |
| 163882 | CNST | P15T-E | Human | Esophagus | ESCC | 3.13e-25 | 5.95e-01 | 0.1149 |
| 163882 | CNST | P16T-E | Human | Esophagus | ESCC | 1.28e-22 | 3.84e-01 | 0.1153 |
| 163882 | CNST | P19T-E | Human | Esophagus | ESCC | 1.49e-02 | 5.39e-01 | 0.1662 |
| 163882 | CNST | P20T-E | Human | Esophagus | ESCC | 3.33e-17 | 4.45e-01 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190307621 | Liver | HCC | regulation of protein localization to plasma membrane | 69/7958 | 104/18723 | 7.58e-07 | 1.17e-05 | 69 |
| GO:000689321 | Liver | HCC | Golgi to plasma membrane transport | 44/7958 | 60/18723 | 1.24e-06 | 1.81e-05 | 44 |
| GO:004300121 | Liver | HCC | Golgi to plasma membrane protein transport | 32/7958 | 40/18723 | 1.40e-06 | 2.01e-05 | 32 |
| GO:190547711 | Liver | HCC | positive regulation of protein localization to membrane | 68/7958 | 106/18723 | 5.50e-06 | 6.82e-05 | 68 |
| GO:006195111 | Liver | HCC | establishment of protein localization to plasma membrane | 41/7958 | 60/18723 | 4.65e-05 | 4.49e-04 | 41 |
| GO:190437712 | Liver | HCC | positive regulation of protein localization to cell periphery | 45/7958 | 69/18723 | 1.16e-04 | 9.80e-04 | 45 |
| GO:190307812 | Liver | HCC | positive regulation of protein localization to plasma membrane | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
| GO:00429961 | Liver | HCC | regulation of Golgi to plasma membrane protein transport | 9/7958 | 10/18723 | 2.79e-03 | 1.31e-02 | 9 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNST | SNV | Missense_Mutation | c.1699G>C | p.Asp567His | p.D567H | Q6PJW8 | protein_coding | deleterious(0.03) | possibly_damaging(0.874) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CNST | SNV | Missense_Mutation | novel | c.255N>C | p.Glu85Asp | p.E85D | Q6PJW8 | protein_coding | tolerated(0.2) | benign(0.024) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CNST | SNV | Missense_Mutation | c.1915N>T | p.His639Tyr | p.H639Y | Q6PJW8 | protein_coding | deleterious(0) | benign(0.058) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| CNST | SNV | Missense_Mutation | c.909N>C | p.Lys303Asn | p.K303N | Q6PJW8 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD | |
| CNST | SNV | Missense_Mutation | c.1023G>C | p.Gln341His | p.Q341H | Q6PJW8 | protein_coding | tolerated(0.06) | benign(0.01) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CNST | insertion | Nonsense_Mutation | novel | c.1534_1535insCCTTTCGGTAACT | p.Gly512AlafsTer4 | p.G512Afs*4 | Q6PJW8 | protein_coding | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| CNST | insertion | Nonsense_Mutation | novel | c.1342_1343insACTACTTTTCTTACATTTAAAATGATGAATGTGTTA | p.Ser448delinsTyrTyrPheSerTyrIleTerAsnAspGluCysValThr | p.S448delinsYYFSYI*NDECVT | Q6PJW8 | protein_coding | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
| CNST | SNV | Missense_Mutation | novel | c.1163N>G | p.Asp388Gly | p.D388G | Q6PJW8 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CNST | SNV | Missense_Mutation | novel | c.394G>C | p.Asp132His | p.D132H | Q6PJW8 | protein_coding | deleterious(0.03) | possibly_damaging(0.789) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| CNST | SNV | Missense_Mutation | rs145890214 | c.1409N>T | p.Ala470Val | p.A470V | Q6PJW8 | protein_coding | tolerated(0.21) | benign(0.024) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |